Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RNF4 | P78317 | 1/20 | 0.46 |
| ▸ | NR3C1 | P04150 | 4/20 | 0.41 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.38 |
| ▸ | PTGES | O14684 | 2/20 | 0.38 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1260140 | 0.86 | MET (0.38) | RNF4SERPINE1NPC1RAB9A | |
| SCHEMBL1258365 | 0.80 | KDR (0.49) | RNF4ALDH1A1HTT | |
| SCHEMBL1260519 | 0.76 | RNF4 (0.51) | RNF4NR3C1SERPINE1PTGESALOX5 | |
| SCHEMBL4443147 | 0.69 | NPC1 (0.54) | SMN1; SMN2GAATSHRNPC1ALDH1A1 | |
| SCHEMBL1260162 | 0.68 | ALDH1A1 (0.48) | RNF4NR3C1PTGESSMN1; SMN2GAA | |
| SCHEMBL1260165 | 0.68 | ALDH1A1 (0.48) | RNF4NR3C1PTGESSMN1; SMN2GAA | |
| SCHEMBL13639124 | 0.67 | PIK3CG (0.40) | SMN1; SMN2GAANPC1ALDH1A1RAB9A | |
| SCHEMBL1927016 | 0.67 | ALDH1A1 (0.69) | SMN1; SMN2GAATSHRNPC1ALDH1A1 | |
| SCHEMBL23518793 | 0.67 | RNF4 (0.85) | RNF4NR3C1PTGESALOX5SMN1; SMN2 | |
| SCHEMBL6727472 | 0.66 | RNF4 (0.53) | RNF4NR3C1SMN1; SMN2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110046169-A1 | FUSED HETEROCYCLIC DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-02-24 | — | — | US | disclosed |
| WO-2009136663-A1 | FUSED HETEROCYCLIC DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046169-A1 | FUSED HETEROCYCLIC DERIVATIVES AND USE THEREOF | ABL1, MAP4K2, MAP3K20 | RNF4 2307/4885NR3C1 1173/4885SERPINE1 4139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.